A Phase 2 Study of Enfortumab Vedotin in People With Adenoid Cystic Carcinoma

Full Title

Phase II Trial of Enfortumab Vedotin in Recurrent and/or Metastatic Adenoid Cystic Carcinoma

Purpose

Researchers want to see how well enfortumab vedotin works in people with adenoid cystic carcinoma. This cancer most often starts in the salivary glands and certain other glands in the body. The people in this study have adenoid cystic cancer that came back or spread after treatment.

Enfortumab vedotin is already used to treat people with bladder cancer. It delivers chemotherapy directly to cancer cells. It attaches to the surface of cancer cells and releases anti-cancer medication inside the cells. Enfortumab vedotin is given intravenously (by vein).

Contact

For more information or to see if you can join this study, please call Dr. Alan Ho’s office at 646-608-3774.